Symptoms and Severity of COVID-19 in Patients with Immune-Mediated Inflammatory Diseases: Experience of a University Medical Center

Table 3

Administered vaccines against SARS-CoV-2.

	No.	%
Entire cohort	156	100
Unvaccinated	10	6.4
Unknown vaccination status	3	1.9
Vaccinated/number of vaccinations
First vaccine	143	91.7
Vaxzevria® (AstraZeneca AB)	12
Comirnaty® (BioNTech GmbH)	114
Jcovden® (Johnson & Johnson)	4
Spikevax® (Moderna Biotech)	13
Second vaccine	136	87.1
Vaxzevria®	4
Comirnaty®	113
Spikevax®	18
Unknown	1
Third vaccine	113	72.4
Vaxzevria®	3
Comirnaty®	83
Spikevax®	25
Unknown	2
Fourth vaccine	11	7.1
Comirnaty®	8
Spikevax®	2
Unknown®	1

SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.